

A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy

Melissa M. Norberg, John H. Krystal, and David F. Tolin

Background: Translational research suggests that D-cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist, might facilitate fear extinction and exposure therapy by either enhancing NMDA receptor function during extinction or by reducing NMDA receptor function during fear memory consolidation. This article provides a quantitative review of DCS-augmented fear extinction and exposure therapy literature.

Methods: English-language journal articles that examined DCS augmented with fear extinction or exposure therapy were identified through public databases from June 1998 through September 2007, through references of originally identified articles and contact with DCS investigators. Data were extracted for study author, title, and year; trial design; type of subject (animal vs. human; clinical vs. nonclinical); sample size, DCS dose, and timing in relation to extinction/exposure procedures; dependent variable; group means and SDs at post-extinction/exposure; and follow-up outcome.

Results: D-cycloserine enhances fear extinction/exposure therapy in both animals and anxiety-disordered humans. Gains generally were maintained at follow-up, although some lessening of efficacy was noted. D-cycloserine was more effective when administered a limited number of times and when given immediately before or after extinction training/exposure therapy.

Conclusions: This meta-analysis suggests that DCS is a useful target for translational research on augmenting exposure-based treatment via compounds that impact neuroplasticity. D-cycloserine's major contribution to exposure-based therapy might be to increase its speed or efficiency, because the effects of DCS seem to decrease over repeated sessions. This information might guide translational researchers in discovering more selective and/or effective agents that effectively enhance (or reduce) NMDA receptor function.

Key Words: Anxiety, D-cycloserine, exposure therapy, extinction, glutamate, neuroplasticity, NMDA

A growing body of evidence suggests that the extinction of fear is mediated by N-methyl-D-aspartate (NMDA) receptor activity in basolateral amygdala (1–7). The NMDA glutamate receptor function can be enhanced indirectly and safely by stimulation of the high-affinity glycine binding site, a feature of the NMDA glutamate receptor complex (8). D-cycloserine (DCS) is a partial agonist of the glycine site and indirectly increases glutamatergic activity in previously “silent” synapses (9). Nevertheless, DCS has complex modulatory actions at NMDA glutamate receptors. When surrounding glycine levels are low, it facilitates NMDA receptor function with up to approximately 60% of the efficacy of glycine, but when glycine levels are sufficient to saturate glycine_B sites, DCS might reduce NMDA receptor function by as much as 40%–50% (10–12). Therefore, DCS might improve the efficacy of exposure-based psychotherapies by enhancing NMDA receptor functioning, thereby increasing neuroplasticity or by reducing NMDA receptor function and interfering with the (re)consolidation of fear memories. Both processes are thought to facilitate fear extinction (13).

Studies of fear extinction in animals suggest that DCS might increase or accelerate extinction effects. In one study by Walker *et al.* (14), rats were conditioned to exhibit a startle reflex toward a light after the light was paired repeatedly with a foot shock. Rats were injected with either saline or DCS (15 mg) and tested

with or without extinction training (light exposure without shock). Only rats that received DCS in addition to extinction training showed a reduction in fear-potentiated startle; rats that received DCS without extinction training did not benefit. In a follow-up experiment, injection of a glycine site antagonist, HA-966, blocked DCS extinction enhancement. These results suggest that the facilitative effects of DCS are not due to any anxiety-attenuating properties but rather to the mediation of the neural mechanisms of extinction. In another experiment performed by these authors, DCS was associated with a dose-dependent enhancement of extinction effects. Rats that received moderate (15 mg/kg) or high (30 mg/kg) DCS doses showed a greater extinction effect (less startle) than those who received a low-dose DCS (3.25 mg/kg); however, there were no differences between rats that received moderate and high DCS doses, suggesting that a moderate dose is sufficient to facilitate extinction. A subsequent study (15) extended the findings of Walker *et al.* (14) with lower DCS doses. At lower doses (2.5, 5, and 10 mg/kg), a dose-response relationship was found when DCS was administered immediately after extinction training. This finding suggests that DCS facilitates extinction by acting on memory consolidation processes that take place after training.

Given the similarity between fear extinction training in animals and exposure-based psychotherapy in humans, translational research from preclinical to clinical work has begun with DCS. In the first study with humans, Ressler *et al.* (16) reported that DCS administration did not affect baseline subjective fear levels in patients receiving virtual reality exposure therapy for specific phobia of heights, replicating the animal findings that the effects of DCS are not due to anxiolytic properties. Patients receiving either 50 or 500 mg DCS seemed to benefit more from virtual reality exposure therapy than patients receiving placebo (PBO). These results have been replicated and extended with 50 to 125 mg of DCS in combination with exposure therapy for patients with social anxiety, panic, and obsessive-compulsive disorder (OCD) (17–20).

From The Institute of Living (MMN, DFT); and Yale University School of Medicine (JHK, DFT), New Haven, Connecticut.

Address reprint requests to David F. Tolin, Ph.D., Anxiety Disorders Center, The Institute of Living, 200 Retreat Avenue, Hartford, CT 06106; E-mail: dtolin@harthosp.org.

Received November 21, 2007; revised January 14, 2008; accepted January 14, 2008.

As the preclinical and clinical studies demonstrating the ability of DCS to augment extinction/exposure therapy accumulate, there is a growing need for a succinct review of this literature. Numerous qualitative reviews of this translational research have identified DCS as a pharmacological agent that facilitates extinction learning in rats and potentially exposure therapy with anxiety-disordered humans (7,21–31). A quantitative description of this literature could allow for stronger inferences to be made regarding the ability of DCS to improve extinction/exposure therapy and provide methodological suggestions for future research.

The present study employed meta-analytic strategies (32) to examine the literature on the ability of DCS to facilitate fear extinction/exposure therapy. Specifically, the effects of fear extinction/exposure therapy combined with DCS were compared with the effects of fear extinction/exposure therapy combined with PBO at post-treatment and follow-up. The effects of DCS also were compared between animals and humans and between nonclinical/subclinical participants and anxiety-disordered humans. Lastly, the moderating effects of dose, dose timing, and number of dose sessions were explored.

Methods and Materials

Data Sources

Journal articles were identified through searches of the Medline and PsychINFO electronic databases from June 1998 through September 2007 with the search terms [(DCS or D-Cycloserine) and (extinction or exposure therapy)] and restricting to the English language. Relevant studies also were identified through references of originally identified articles and contact with DCS investigators. This literature search identified 44 articles, which then were examined for inclusion.

Study Selection

Randomized, PBO-controlled trials were included if: 1) sufficient information was provided to compute effect sizes (or necessary additional information was supplied by the authors) and if they 2) examined DCS augmented with fear extinction in animals or humans or 3) examined DCS augmented with exposure therapy for clinical or nonclinical anxiety in humans. From the original pool, 29 articles were excluded from analysis. Reasons for study exclusion included the following:

1. The article was a review that did not present new data or only presented qualitative information ($n = 12$) (7,21–31).
2. The article examined the effects of DCS on something other than fear extinction, such as perception or impulsive behavior ($n = 7$) (33–39).
3. The article tested the effects of DCS after exposure to a drug of abuse ($n = 3$) (40–42).
4. The article tested DCS in conjunction with another substance ($n = 2$) (43,44).
5. Extinction training varied between PBO and DCS groups ($n = 1$) (45).
6. Sufficient information to compute effect sizes could not be obtained either from the article or from the primary author ($n = 4$) (46–49).

The 15 resultant articles yielded 30 independent samples comparing DCS versus PBO. Of the samples included in the meta-analysis, 10 included humans and 2 of them examined nonclinical participants.

Data Extraction

Data were extracted for study author, title, and year; trial design; type of subject (animal vs. human; clinical vs. nonclinical); sample size, DCS dose, and timing in relation to extinction/exposure procedures; dependent variable; and group means and SDs at post-extinction/exposure and (when available) at follow-up. Data were extracted by one of the authors and verified by another author. Table 1 shows the studies used in the present meta-analysis.

For three of the human clinical studies, multiple potential dependent measures were available. Two studies of OCD (19,20) found a significant DCS versus PBO effect after 5 sessions but not after 10. Because the timing of DCS effects in longer trials is not yet well understood, only data from the fifth session were extracted. One study of social phobia (50) employed three different standardized self-report measures of social anxiety. Because two of them are not commonly used in trials of experimental medications, only the outcomes for a measure widely used in clinical trials, the Liebowitz Social Anxiety Scale (51), were retained. These choices might increase the likelihood of Type I error by inflating the effect size for clinical samples; however, given the relative novelty of DCS augmentation and the exploratory nature of the present analysis, it was felt that this risk was preferable to the possibility of missing a clinically meaningful effect.

Data Synthesis

Data were analyzed with Comprehensive Meta-Analysis v.2.2 software. For each comparison of a DCS versus PBO sample, we calculated Cohen's d . A d value of .0 indicates no difference between DCS and PBO participants; conventionally, .2, .5, and .8 are taken to represent small, medium, and large effects, respectively (52). We also calculated the 95% confidence interval (CI), statistical significance (p), and within-group heterogeneity (Q_{within}) for each effect size estimate. Effect size estimates are considered significantly different from one another when their 95% CIs do not overlap. For additional clarification of differences between effect size estimates, we calculated the mixed-effects between-group heterogeneity (Q_{between}). An initial test of homogeneity of variance indicated heterogeneity across samples, $Q_{\text{within}}(29) = 74.18, p < .001$; therefore, random-effects models were used. Studies varied according to sample size (range 15–63); this creates a risk that a small, outlying sample will exert disproportionate influence over the mean effect size. To minimize this risk, we weighted effect size estimates by sample size (53). To test the so-called “file drawer effect” (the probability that unpublished null results would eliminate the obtained results), for each significant result we computed the “fail-safe N ” (FSN) or the number of null results that would be needed to overturn a significant result. For the present analyses, we examined the number of studies that would make $p > .05$. Generally, if the $\text{FSN} \geq 5$ times the number of studies in the analysis + 10 ($\text{FSN} \geq 5k + 10$), the obtained results are considered robust against the file drawer effect (53). In addition to more traditional measures (questionnaires and interviews), some of the human studies also used dependent variables that are atypical in clinical trials (e.g., shock expectancy ratings, skin conductance changes). To maximize consistency across studies, data for the human studies were limited to the best-available measure of subjective symptoms, such as semistructured interviews (18,19,54), standardized self-report (17,50), or when these were not available, subjective fear ratings (16,20,55). Moderator variables (dose, dose timing, number of sessions) were tested with linear regression analyses. The

Table 1. Studies Included in the Meta-Analysis

Study Name	<i>d</i> (post)	<i>d</i> (FU)	HED (mg/kg)	Dose Timing	Measure	# Sessions
Animal Studies						
Ledgerwood <i>et al.</i> (15) Study 1	1.22	—	2.42	–.25	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 2	3.49	.02	2.42	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 3	1.43	—	1.61	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 3	.54	—	.40	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 3	.80	—	.81	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 4	2.76	—	2.42	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 4	1.43	—	2.42	2.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 4	.84	—	2.42	4.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 4	2.63	—	2.42	.90	% Time Freezing	1
Ledgerwood <i>et al.</i> (15) Study 5	1.26	—	1.61	.40	% Time Freezing	1
Ledgerwood <i>et al.</i> (66)	1.09	2.42	2.42	.40	% Time Freezing	1
Lee <i>et al.</i> (81)	.93	—	2.42	–.33	% Time Freezing	1
Lee <i>et al.</i> (81)	1.91	—	2.42	.00	% Time Freezing	1
Parnas <i>et al.</i> (57)	1.88	—	2.42	.40	% Time Freezing	1
Walker <i>et al.</i> (14)	1.17	—	—	–.25	% Increase Startle	1
Weber <i>et al.</i> (68) Study 1	.05	—	2.42	.43	% Time Freezing	1
Weber <i>et al.</i> (68) Study 2	1.05	—	2.42	.43	% Time Freezing	1
Weber <i>et al.</i> (68) Study 4	1.25	—	2.42	.43	% Time Freezing	1
Woods & Bouton (82)	–.50	—	2.42	–.25	Suppression ratio	1
Woods & Bouton (82)	.69	—	4.84	–.25	Suppression ratio	1
Human Nonclinical Studies						
Guastella <i>et al.</i> (55) Study 1	–.21	–.11	.83	–2.50	SUDS	1
Guastella <i>et al.</i> (55) Study 2	.00	–.43	4.58	–2.50	SUDS	1
Human Clinical Studies						
Specific phobia						
Ressler <i>et al.</i> (16)	.36	.27	.83	–3.00	SUDS	2
Ressler <i>et al.</i> (16)	.86	.47	8.33	–3.00	SUDS	2
Social phobia						
Guastella <i>et al.</i> (50)	.65	—	.83	–1.00	LSAS	4
Hofmann <i>et al.</i> (17)	.43	.80	.83	–1.00	SIAS	4
Panic Disorder						
Tolin <i>et al.</i> (18)	1.11	.86	.83	–1.00	PDSS	3
Obsessive-Compulsive Disorder						
Kushner <i>et al.</i> (20)	.89 ^a	.43	2.08	–2.00	SUDS	5
Storch <i>et al.</i> (54)	–.19	–.36	4.17	–4.00	Y-BOCS	12
Wilhelm <i>et al.</i> (19)	.70 ^a	.57	1.67	–1.00	Y-BOCS	5

d, Cohen's *d*; FU, follow-up; HED, human equivalent dose; SUDS, subjective units of discomfort (83); LSAS, Liebowitz Social Anxiety Scale (51); SIAS, Social Interaction Anxiety Scale (84); PDSS, Panic Disorder Severity Scale (85); Y-BOCS, Yale-Brown Obsessive-Compulsive Scale (86).

^aSession 5 data used for post-treatment effect size.

DCS dose was standardized across studies by calculating human equivalent dose (HED) in mg/kg with formulas set by the U.S. Food and Drug Administration (56). This was done only for studies using systemic DCS administration; studies using intra-amygdala administration (14,15) were not used for dose-response analyses. Dose timing was calculated as the number of hours before the beginning of extinction/exposure that DCS was administered (negative numbers indicate that DCS was administered before the beginning of extinction/exposure; positive numbers indicate that DCS was administered after the beginning of extinction/exposure; a score of 0 indicates that DCS was administered exactly at the beginning of extinction/exposure). Number of sessions indicates the number of concurrent DCS + extinction/exposure sessions that were used. Studies in which multiple doses of DCS were given in the absence of extinction/exposure (57) were not included in this analysis.

Results

Effect sizes (Cohen's *d*) for all studies and specific subgroups are shown in Table 2. At post-treatment (Table 2), human studies

were compared with studies of animals. This comparison yielded a significant difference ($Q_{\text{between}} = 10.18$), with greater effects seen in animal studies. Both animal and human studies nevertheless were associated with significant effect sizes, with a large and robust effect in animal studies ($d = 1.19$) and a small (but not robust) effect in human studies ($d = .42$). Although within-group heterogeneity in the human studies was not statistically significant ($p = .08$), we wondered whether the outcomes for the two nonclinical human samples (55) might differ from those of clinical samples. This comparison yielded a significant difference ($Q_{\text{between}} = 8.57$). The effect for the two nonclinical samples was not significant (in fact, the effect neared the small range in the opposite direction, with PBO seeming slightly superior to DCS, $d = -.16$). The human clinical studies showed a moderate effect ($d = .60$), although this effect remained lower than that of the animal studies ($Q_{\text{between}} = 6.61$). Examining all studies together, DCS was associated with a significant overall effect size versus PBO when added to extinction/exposure. This effect was in the large range ($d = .90$) and is considered robust against the file-drawer effect.

Table 2. Effect Sizes and Comparisons Across Subgroups of Studies

Comparison	k	n	d	95% CI	FSN	Q_{within}	$Q_{between}$
Post-Treatment							
Animal	20	336	1.19 ^a	.84–1.54	473 ^b	40.09 ^c	
Human	10	296	.42 ^c	.11–.74	22	15.38	
Animal vs. human							10.18 ^a
Human clinical	8	212	.60 ^a	.33–.88	29	6.62	
Human nonclinical	2	84	–.16	–.59–.27	—	.19	
Human clinical vs. nonclinical							8.57 ^c
Human clinical vs. animal							6.61 ^c
All studies	30	632	.90 ^a	.62–1.18	743 ^b	74.18 ^a	
Follow-Up							
Animal	2	36	1.20	–1.14–3.55	—	9.64 ^c	
Human	10	292	.29 ^c	.01–.57	5	12.10	
Animal vs. human							.58
Human clinical	8	208	.47 ^a	.19–.75	13	5.28	
Human nonclinical	2	84	–.19	–.62–.24	—	.40	
Human clinical vs. nonclinical							6.42 ^c
Human clinical vs. animal							.37
All studies	12	328	.40 ^c	.05–.75	24	25.31 ^c	

k, number of independent samples; n, number of participants; d, Cohen's d; CI, confidence interval; FSN, fail-safe n; Q_{within} , within-group homogeneity of variance; $Q_{between}$, between-group homogeneity of variance.

^a $p < .001$.

^bRobust against the file-drawer effect (FSN > 5k + 10).

^c $p < .05$.

A minority of studies included follow-up data (Table 2). Animal and human studies did not differ significantly from each other ($Q_{between} = .58$). Only human studies were associated with a significant effect size ($d = .29$), although the effect size was numerically much higher for animal studies than for human studies ($d = 1.20$). As was the case for the post-treatment data, a significant difference was obtained between human clinical and nonclinical studies ($Q_{between} = 6.42$), with clinical studies showing a significant and small (although not robust) effect size ($d = .47$) and nonclinical studies showing no effect ($d = -.19$). Animal and human clinical studies did not differ significantly from each other ($Q_{between} = .37$). Across all available studies, DCS augmentation was associated with a significant and small effect size ($d = .40$), although this was not robust against the file drawer effect.

Next, we examined the effect of potential moderating variables on the effect of DCS versus PBO at post-treatment. Regression analyses (Figure 1) showed that DCS dose (HED) was not significantly associated with DCS effect ($z = .51$, $p = .61$); this was true for subgroups of animal, human clinical, and human nonclinical studies (not shown). The timing of the DCS dose significantly predicted effect size ($z = 4.53$, $p < .001$), with the greatest effects evident among studies in which DCS was administered either immediately before or after exposure/extinction. Studies in which DCS was administered multiple hours before exposure/extinction had smaller effects. Number of DCS + exposure/extinction sessions also predicted treatment outcome ($z = -2.19$, $p = .03$), with smaller effects seen for those studies in which DCS + exposure was given many times. Visual examination of Figure 1 suggests that this effect might have been the result of one outlying study (54); when this study was eliminated from analysis, there was no longer a significant relationship between treatment outcome and number of DCS + exposure sessions ($z = -.47$, $p = .64$). For additional exploration of the relationship between number of sessions and DCS effect, we examined three OCD treatment outcome studies (19,20,54) in which DCS was compared with PBO at mid- and post-treatment.

As shown in Figure 2, all three studies showed a parallel decrease in DCS efficacy over time.

Discussion

The results of the present meta-analysis suggest that DCS augments the effects of fear extinction/exposure therapy in both animals and humans. Across all samples, the effect size was large, indicating a substantial increase in efficacy. Although there is ample evidence that exposure-based treatment is effective for the treatment of anxiety disorders, many patients fail to respond adequately to treatment—for example, in studies of panic disorder, only one-half of treated patients met criteria for recovery/high end-state functioning (58,59), and many patients seek additional treatment within two years after termination (60). Although it might be expected that combining exposure-based therapy with traditional antidepressant or anxiolytic pharmacotherapy would be more effective than therapy alone, the literature to date has not supported this hypothesis. For example, recent large-scale trials for social phobia (61), OCD (62), and panic disorder (63) failed to provide compelling evidence of a long-term beneficial effect of adding antidepressant medications to exposure-based therapy; similar findings have been obtained in studies augmenting exposure-based therapy with benzodiazepines (64). Rather than an additive approach in which anxiety-reducing psychotherapy and pharmacotherapy are combined, DCS augmentation is based on an interactive model in which the pharmacotherapy systematically targets and augments the proposed neural mechanism of the psychotherapy.

Animal studies evidenced greater and more robust effects than human studies; however, this difference was attenuated when nonclinical human studies were removed from the analyses. The two nonclinical studies found no evidence of DCS augmentation in experimentally induced fear when using a differential shock paradigm (46) or when using exposure therapy for subclinical spider phobia (55). These results might be explained by a ceiling effect: 100% of the subclinical spider




Figure 1. Regressions of moderator variables against effect size. DCS, D-cycloserine; HED, human equivalent dose.

fearful participants completed all behavioral assignments over a 2-hour exposure session, which included handling large spiders that can produce painful bites (55). Typically, healthy participants or mildly phobic individuals do not require

extensive extinction training to return to preconditioning levels.

A greater effect in animal studies is perhaps not surprising, given the greater experimental control over extraneous variables




Figure 2. Effect sizes at mid- (Mid-Tx) and post-treatment (Post-Tx) for three studies of D-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder.

in animal studies. In animal studies, subjects only receive extinction training in the presence or absence of DCS, whereas human patients are able to expose themselves to their feared situations outside of the therapeutic context. In addition, research animals are highly inbred, and thus results would be expected to be less variable.

Also noteworthy, the human studies were not robust against the “file drawer” effect, likely owing to the relatively small number and sample sizes of existing studies (e.g., 8 human clinical studies with $n = 84$, compared with 20 animal studies with $n = 336$). Nevertheless, the generally comparable findings across animal and human studies suggest that DCS is a promising tool for translational research concerned with enhancing (or reducing) NMDA receptor function as a method for improving exposure-based therapy outcomes.

Relatively few studies have examined the long-term effects of DCS on fear extinction/exposure therapy, although the existing studies show significant and moderate effect sizes at follow-up. When analyzing animal and human studies separately, only human studies were associated with a significant effect size at follow-up. This finding is likely due to the small number of animal samples that provided follow-up data, as the effect size for animal studies was numerically higher than human studies. Similar to post-treatment data, nonclinical human studies were not associated with a significant effect of DCS at follow-up. These preliminary results suggest that the effects of DCS augmentation do not disappear upon treatment discontinuation, a potential improvement over other pharmacotherapy augmentation strategies that might actually increase the risk of relapse after discontinuation (63,64).

The present results indicate that the augmenting effect of DCS is potentially dependent on the timing and number of doses. These factors are perhaps best illustrated by Storch *et al.* (54), who did not find a positive effect of DCS versus PBO. Unlike the two other OCD trials (19,20), Storch *et al.* administered DCS for a longer period of time (12 weeks vs. 5 weeks) and used a longer duration between administration and initiation of an exposure session (4 hours vs. 1–2 hours). Figure 1 clearly shows the Storch *et al.* study as an outlier in terms of these two variables. When this study was removed from analysis, the number of DCS augmented fear extinction/exposure therapy sessions was not related significantly to outcome; however, when the study was included in the analysis, smaller effects were seen for those studies that used a greater number of sessions. The finding that the number of sessions was related negatively to outcome is

tentative, because two of the effect sizes used for the human studies (both samples of OCD patients) were selected post hoc from time points when a separation occurred from DCS and PBO (19,20). Given the number of uncertainties in DCS research, the mid-treatment time point was used so that potential differences between DCS and PBO would not be missed; however, across all three OCD studies, the effect of DCS decreased over repeated sessions. This decrease might be the result of desensitization to DCS (57) or it might reflect floor effects of repeated exposures (i.e., with enough exposure therapy there might be little need for augmentation). This suggests that DCS's major contribution to exposure-based therapy might be to increase its speed or efficiency. Consistent with this suggestion, Ledgerwood *et al.* (65) have demonstrated in animals that DCS can block the reinstatement of previously extinguished fear and that its effects can generalize to non-extinguished conditioned stimuli (66). Increasing the speed of treatment is a worthwhile pursuit, because it might be expected to lead to reduced attrition, increased satisfaction, decreased treatment cost, increased ease of dissemination to primary care, and decreased economic burden of illness.

The finding that DCS is most effective when administered immediately before or after fear extinction/exposure therapy suggests that the augmenting effects of DCS take place during the period of memory consolidation that occurs after training. Animal studies using NMDA receptor antagonists at various intervals after extinction training suggest that NMDA-dependent fear extinction occurs in waves lasting 1–2 days after training, as hippocampal-neocortical synaptic connections are strengthened (67). Because DCS reaches peak plasma levels 4–8 hours after oral administration, drug levels would be expected to be highest during the period of post-session memory consolidation if administered after a fear extinction/exposure therapy session. Another potential benefit of administering DCS immediately after fear extinction/exposure therapy sessions is the possibility for the clinician to administer DCS only after sessions in which within-session extinction has occurred. This procedure would be consistent with animal research showing that DCS leads to long-term gains only for animals exhibiting within-session extinction (68). Such selective administration would also lessen the possibility of tolerance due to chronic administration, as described in the preceding text.

The DCS dose was not significantly associated with DCS effect in any subgroup. This null finding should be considered tentative, because only two studies to date have compared multiple

doses within a single study. Ledgerwood *et al.* (15) found effects of .54, .80, and 1.43 for DCS versus PBO in rats with 2.5 mg, 5 mg, and 10 mg, respectively, whereas Ressler *et al.* (16) found effects of .36 and .86 for DCS versus PBO in phobic humans with 50 mg and 500 mg, respectively. In both of these studies a pattern of greater effects was evidenced at higher doses.

The beneficial effects of DCS in anxiety disorders contrast with findings from the use of DCS as a corrective treatment for neurocognitive deficits in schizophrenia and Alzheimer's disease (69,70). Despite early promising results (71–73), larger and more recent trials (74–76) yielded generally nonsignificant findings relative to PBO (70,77). In the treatment of schizophrenia and Alzheimer's disease, D-cycloserine has been applied in chronic daily doses, unlike the extinction-augmenting applications used in treatments of conditioned fear. As shown by the present results, isolated dosing might be more effective than chronic dosing for specific learning-based purposes, consistent with the demonstration of desensitization of the NMDA receptor complex in cell culture with prolonged exposure to DCS and other glycinergic ligands (78).

Many questions remain unanswered concerning the usefulness of DCS augmented exposure therapy. For example, additional dose-finding research in animals and humans is needed to clarify how DCS might interact with other common psychiatric medications. We excluded, as noted previously, two animal studies in which DCS was administered concurrently with other medications (43,44). Yet, many of the human clinical studies included patients that received concurrent pharmacotherapy. Thus, it might initially seem that the inclusion criteria for the meta-analysis differed across human and animal studies; however, the retained human clinical studies required a period of medication stability that allows for a more definitive examination of the effects of DCS, unlike the two animal studies that were excluded. One animal study (79) found that rats pre-exposed to imipramine over 14 days showed reduced DCS facilitation of extinction training. Human trials of DCS administered along with antidepressant and benzodiazepine medications would clarify this issue for clinical practice.

Another direction for future research is to examine whether DCS is effective for individuals who have not successfully responded to prior trials of exposure-based monotherapy. Such application would likely reflect typical clinical practice, in which novel or "off label" compounds are administered after the failure of more conventional treatments. To the extent that treatment failure is due to inadequate within- or between-session extinction, DCS augmentation might be expected to enhance outcomes.

In addition, DCS needs to be examined in the treatment of a broader range of anxiety-related conditions. Early studies (16,29) treated phobic disorders that are fairly homogeneous and whose treatment is easily standardized. Recent results with chronic and heterogeneous conditions such as OCD (19,20,54) have been more mixed but overall seem consistent with the previous findings. Additional research with conditions such as posttraumatic stress disorder, also treated with exposure-based interventions (80), would help clarify the range of DCS applicability.

Drs. Norberg and Tolin were supported by grants from Hartford Hospital and the National Institute of Mental Health. Drs. Norberg and Tolin reported no biomedical financial interests or potential conflicts of interest. Dr. Krystal has served as a paid scientific consultant to: Bristol-Myers Squibb, Cypress Bioscience, Eli Lilly, Forest Laboratories, GlaxoSmith-Kline, Janssen

Research Foundation, Merz Pharmaceuticals, Organon Pharmaceuticals, Pfizer Pharmaceuticals, Shire Pharmaceuticals, Takeda Industries, UCB Pharma, and US Micron. He is also co-sponsor of two pending patents related to the use of glutamatergic agents to treat psychiatric disorders. Dr. Krystal was supported by the Department of Veterans Affairs National Center for PTSD and the National Institute on Alcohol Abuse and Alcoholism.

We wish to thank Drs. Mark Bouton, Adam Guastella, Stefan Hofmann, Matt Kushner, Joff Lee, Kwok-Tung Lu, Kerry Ressler, Rick Richardson, Eric Storch, and David Walker for providing papers and data. Without their help this meta-analysis could not have been conducted.

1. Baker JD, Azorlosa JL (1996): The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. *Behav Neurosci* 110:618–620.
2. Royer S, Pare D (2002): Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. *Neuroscience* 115:455–462.
3. Cox J, Westbrook RF (1994): The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. *Q J Exp Psychol B* 47:187–210.
4. Fanselow MS, LeDoux JE (1999): Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. *Neuron* 23:229–232.
5. Goosens KA, Maren S (2002): Long-term potentiation as a substrate for memory: Evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning. *Hippocampus* 12:592–599.
6. Rogan MT, Staubli UV, LeDoux JE (1997): Fear conditioning induces associative long-term potentiation in the amygdala. *Nature* 390:604–607.
7. Davis M (2002): Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: Clinical implications for exposure therapy. *Eur J Neurosci* 16:395–398.
8. D'Souza DC, Charney DS, Krystal JH (1995): Glycine site agonists of the NMDA receptor: A review. *CNS Drug Reviews* 1:227–260.
9. Gomperts SN, Rao A, Craig AM, Malenka RC, Nicoll RA (1998): Postsynaptically silent synapses in single neuron cultures. *Neuron* 21:1443–1451.
10. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991): Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. *Neuropharmacology* 30:1167–1171.
11. Hood WF, Compton RP, Monahan JB (1989): D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. *Neurosci Lett* 98:91–95.
12. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990): D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in *Xenopus* oocytes. *Brain Res* 510:158–160.
13. Krystal JH (2007): Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: New opportunities for synergy with psychotherapy. *Biol Psychiatry* 62:833–834.
14. Walker DL, Ressler KJ, Lu KT, Davis M (2002): Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. *J Neurosci* 22:2343–2351.
15. Ledgerwood L, Richardson R, Cranney J (2003): Effects of D-cycloserine on extinction of conditioned freezing. *Behav Neurosci* 117:341–349.
16. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, *et al.* (2004): Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. *Arch Gen Psychiatry* 61:1136–1144.
17. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, *et al.* (2006): Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. *Arch Gen Psychiatry* 63:298–304.
18. Tolin DF, Pearlson GD, Krystal JH, Davis M, Meunier SA, Brady RS, *et al.* (2007): A controlled trial of d-cycloserine with brief CBT for panic disorder. Presented at the Annual Meeting of the World Congress of Behavioral and Cognitive Therapies, July 2007, Barcelona, Spain.

19. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearson GD, Reese HE, *et al.* (2008): D-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder. *Am J Psychiatry* Epub ahead of print: February 1.
20. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, *et al.* (2007): D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. *Biol Psychiatry* 62:835–838.
21. Davis M, Myers KM, Ressler KJ, Rothbaum BO (2005): Facilitation of extinction of conditioned fear by d-cycloserine. *Curr Dir Psychol Sci* 14:214–219.
22. Davis M (2006): Neural systems involved in fear and anxiety measured with fear-potentiated startle. *Am Psychol* 61:741–756.
23. Birk L (2004): Pharmacotherapy for performance anxiety disorders: Occasionally useful but typically contraindicated. *J Clin Psychol* 60:867–879.
24. Davis M, Ressler K, Rothbaum BO, Richardson R (2006): Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. *Biol Psychiatry* 60:369–375.
25. Davis M, Walker DL, Myers KM (2003): Role of the amygdala in fear extinction measured with potentiated startle. *Ann NY Acad Sci* 985:218–232.
26. Garakani A, Mathew SJ, Charney DS (2006): Neurobiology of anxiety disorders and implications for treatment. *Mt Sinai J Med* 73:941–949.
27. Gillespie CF, Ressler KJ (2005): Emotional learning and glutamate: Translational perspectives. *CNS Spectrums* 10:831–839.
28. Hofmann SG (2007): Enhancing exposure-based therapy from a translational research perspective. *Behav Res Ther* 45:1987–2001.
29. Hofmann SG, Pollack MH, Otto MW (2006): Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. *CNS Drug Reviews* 12:208–217.
30. Otto MW, Basden S, Leyro TM, McHugh KM, Hofmann SG (2007): Clinical perspectives on the combination of d-cycloserine and CBT for the treatment of anxiety disorders. *CNS Spectrums* 12:51–56, 59–61.
31. Richardson R, Ledgerwood L, Cranney J (2004): Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. *Learn Mem* 11:510–516.
32. Glass GV, McGaw B, Smith ML (1981): *Meta-Analysis in Social Research*. London: Sage Publications.
33. Bailey JE, Papadopoulos A, Lingford-Hughes A, Nutt DJ (2007): D-Cycloserine and performance under different states of anxiety in healthy volunteers. *Psychopharmacology (Berl)* 193:579–585.
34. Britton JC, Gold AL, Feczko EJ, Rauch SL, Williams D, Wright CI (2007): D-cycloserine inhibits amygdala responses during repeated presentations of faces. *CNS Spectrums* 12:600–605.
35. Gabriele A, Packard MG (2007): D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction. *Learn Mem* 14:468–471.
36. Port RL, Seybold KS (1998): Manipulation of NMDA-receptor activity alters extinction of an instrumental response in rats. *Physiol Behav* 64:391–393.
37. van den Bergh FS, Bloemarts E, Groenink L, Olivier B, Oosting RS (2006): Delay aversion: Effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and D-cycloserine. *Pharmacol Biochem Behav* 85:736–743.
38. Van Vleet TM, Heldt SA, Pyter B, Corwin JV, Reep RL (2003): Effects of light deprivation on recovery from neglect and extinction induced by unilateral lesions of the medial agranular cortex and dorsocentral striatum. *Behav Brain Res* 138:165–178.
39. VanVleet TM, Heldt SA, Guerrettaz KR, Corwin JV, Reep RL (2002): Unilateral destruction of the dorsocentral striatum in rats produces neglect but not extinction to bilateral simultaneous stimulation. *Behav Brain Res* 136:375–387.
40. Bertotto ME, Bustos SG, Molina VA, Martijena ID (2006): Influence of ethanol withdrawal on fear memory: Effect of D-cycloserine. *Neuroscience* 142:979–990.
41. Botreau F, Paolone G, Stewart J (2006): D-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. *Behav Brain Res* 172:173–178.
42. Kelley JB, Anderson KL, Itzhak Y (2007): Long-term memory of cocaine-associated context: Disruption and reinstatement. *Neuroreport* 18:777–780.
43. Akirav I (2007): NMDA Partial agonist reverses blocking of extinction of aversive memory by GABA(A) agonist in the amygdala. *Neuropsychopharmacology* 32:542–550.
44. Yang YL, Chao PK, Ro LS, Wo YY, Lu KT (2007): Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. *Neuropsychopharmacology* 32:1042–1051.
45. Ledgerwood L, Richardson R, Cranney J (2004): D-cycloserine and the facilitation of extinction of conditioned fear: Consequences for reinstatement. *Behav Neurosci* 118:505–513.
46. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R (2007): A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. *Behav Res Ther* 45:663–672.
47. Mao SC, Hsiao YH, Gean PW (2006): Extinction training in conjunction with a partial agonist of the glycine site on the NMDA receptor erases memory trace. *J Neurosci* 26:8892–8899.
48. Tomilenko RA, Dubrovina NI (2007): Effects of activation and blockade of NMDA receptors on the extinction of a conditioned passive avoidance response in mice with different levels of anxiety. *Neurosci Behav Physiol* 37:509–515.
49. Yang YL, Lu KT (2005): Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. *Neuroscience* 134:247–260.
50. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR (2007): A randomised controlled trial of d-cycloserine enhancement of exposure therapy for social phobia. *Biol Psychiatry* 63:544–549.
51. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR (1999): Psychometric properties of the Liebowitz Social Anxiety Scale. *Psychol Med* 29:199–212.
52. Cohen J (1988): *Statistical Power Analysis for the Behavioral Sciences, 2nd ed.* Hillsdale, New Jersey: Lawrence Erlbaum Associates.
53. Rosenthal R (1991): *Meta-Analytic Procedures for Social Research*. London: Sage Publications.
54. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, *et al.* (2007): D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. *Int Clin Psychopharmacol* 22:230–237.
55. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R (2007): A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. *J Psychiatr Res* 41:466–471.
56. U.S. Food and Drug Administration (2005): *Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers*. Rockville, Maryland: U.S. Food and Drug Administration.
57. Parnas AS, Weber M, Richardson R (2005): Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. *Neurobiol Learn Mem* 83:224–231.
58. Margraf J, Barlow DH, Clark DM, Telch MJ (1993): Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow-up. *Behav Res Ther* 31:1–8.
59. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M (1994): A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. *Br J Psychiatry* 164:759–769.
60. Brown TA, Barlow DH (1995): Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. *J Consult Clin Psychol* 63:754–765.
61. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, *et al.* (2004): Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. *Arch Gen Psychiatry* 61:1005–1013.
62. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, *et al.* (2005): Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. *Am J Psychiatry* 162:151–161.
63. Barlow DH, Gorman JM, Shear MK, Woods SW (2000): Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. *JAMA* 283:2529–2536.
64. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, *et al.* (1993): Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. *Br J Psychiatry* 162:776–787.
65. Ledgerwood L, Richardson R, Cranney J (2004): D-cycloserine and the facilitation of extinction of conditioned fear: Consequences for reinstatement. *Behav Neurosci* 118:505–513.
66. Ledgerwood L, Richardson R, Cranney J (2005): D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. *Biol Psychiatry* 57:841–847.

67. Santini E, Muller RU, Quirk GJ (2001): Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. *J Neurosci* 21:9009–9017.
68. Weber M, Hart J, Richardson R (2007): Effects of D-cycloserine on extinction of learned fear to an olfactory cue. *Neurobiol Learn Mem* 87:476–482.
69. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN (1994): D-cycloserine treatment of Alzheimer disease. *Alzheimer Dis Assoc Disord* 8:198–205.
70. Tuominen HJ, Tiihonen J, Wahlbeck K (2005): Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. *Schizophr Res* 72:225–234.
71. Goff DC, Tsai G, Levitt J, *et al.* (1999): A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Arch Gen Psychiatry* 56:21–27.
72. Goff DC, Coyle JT (2001): The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. *Am J Psychiatry* 158:1367–1377.
73. Tsai GE, Falk WE, Gunther J, Coyle JT (1999): Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. *Am J Psychiatry* 156:467–469.
74. Goff DC, Herz L, Posever T, *et al.* (2005): A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. *Psychopharmacology (Berl)* 179:144–150.
75. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, *et al.* (2004): Effects of D-cycloserine on negative symptoms in schizophrenia. *Schizophr Res* 71:239–248.
76. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, *et al.* (1995): Evaluation of cycloserine in the treatment of Alzheimer's disease. *J Geriatr Psychiatry Neurol* 8:226–230.
77. Laake K, Oeksengaard AR (2002): D-cycloserine for Alzheimer's disease. *Cochrane Database Syst Rev* (2):CD003153.
78. Boje KM, Wong G, Skolnick P (1993): Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. *Brain Res* 603:207–214.
79. Werner-Seidler A, Richardson R (2007): Effects of D-cycloserine on extinction: Consequences of prior exposure to imipramine. *Biol Psychiatry* 62:1195–1197.
80. Foa EB, Hembree EA, Cahill SP, Rauch SA, Riggs DS, Feeny NC, Yadin E (2005): Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. *J Consult Clin Psychol* 73:953–964.
81. Lee JL, Milton AL, Everitt BJ (2006): Reconsolidation and extinction of conditioned fear: Inhibition and potentiation. *J Neurosci* 26:10051–10056.
82. Woods AM, Bouton ME (2006): D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. *Behav Neurosci* 120:1159–1162.
83. Wolpe J (1990): *The Practice of Behavior Therapy, 4th ed.* New York: Pergamon Press.
84. Mattick RP, Clarke JC (1998): Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behav Res Ther* 36:455–470.
85. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, *et al.* (1997): Multicenter collaborative panic disorder severity scale. *Am J Psychiatry* 154:1571–1575.
86. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, *et al.* (1989): The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch Gen Psychiatry* 46:1006–1011.

Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects

Alexander Neumeister, MD,* Richard Carson, PhD,† Shannan Henry, MS,* Beata Planeta-Wilson, MS,‡
Brendon Binneman, MD,‡ R. Paul Maguire, PhD,‡ David A. Luckenbaugh, MA,§ Cyril D'Souza, MD,*
John H. Krystal, MD,* and J. James Frost, MD, PhD†

Abstract: Enhancing *N*-methyl-D-aspartate (NMDA) receptor function via increasing synaptic concentrations of glycine is currently investigated as a novel approach to treat schizophrenia. The neural correlates of enhanced NMDA receptor function in humans, however, are unclear to date. The present study determines the effects of intravenous administration of the glycine on regional cerebral metabolic rate of glucose (rCMRGlu) in healthy control subjects by using [¹⁸F]fluorodeoxyglucose and positron emission tomography and on neuropsychological behavioral measures. Thirteen healthy volunteers were recruited, and 12 subjects completed the protocol. These individuals participated in 1 magnetic resonance imaging study and 2 [¹⁸F]fluorodeoxyglucose positron emission tomography studies. In a double-blind, randomized, controlled, crossover design, participants received on one test day an intravenous glycine infusion and on the other test day a placebo infusion. There were no significant behavioral and neuropsychological effects of glycine compared with placebo. However, there was a significant reduction of whole-brain CMRGlu during administration of glycine compared with placebo ($t = 2.60$, $df = 11$, $P = 0.023$). In the a priori–selected regions of interest, there was a significant reduction in the cerebellum ($t = -3.18$, $df = 11$, $P = 0.009$) and the dorsolateral prefrontal cortex ($t = -2.31$, $df = 11$, $P = 0.041$). When corrected for whole-brain CMRGlu, rCMRGlu differences were not significant. This study suggests that studies of whole-brain cerebral metabolism may be useful for studying glycine-related mechanisms in healthy humans because there is not a clear cognitive or behavioral signal related to glycine administration at doses thought to be important clinically in patient populations.

(*J Clin Psychopharmacol* 2006;26:595–599)

Glycine is a coagonist of *N*-methyl-D-aspartate glutamate receptors (NMDARs), which is essential for ion channel

opening and for the internalization of the NMDAR from the cell surface.^{1,2} The high concentrations of glycine in the plasma, cerebrospinal fluid (CSF), and brain extracellular fluid suggested that the glycine modulatory site of the NMDAR might be saturated under physiological conditions. For example, the affinity of glycine for the glycine modulatory site (glycine_B) ranges from 0.1 to 0.3 μmol/L, depending on the NR2 subtype of the NMDAR,³ and glycine concentrations in the CSF is 5–10 μmol/L. However, more recent studies indicate that the high-activity glycine transporter (GlyT1) has sufficiently high maximal activity to produce synaptic glycine levels below that which produces saturation of glycine_B sites.⁴ Subsequent physiological data further indicated that GlyT inhibitors augment NMDA receptor function in animals.^{5–7} GlyT1 inhibition produces a behavioral profile consistent with antipsychotic efficacy in rodents,⁸ and there is emerging evidence that GlyT inhibitors may be effective antipsychotics.⁹ Gene knockout of the GlyT1 also enhanced hippocampal NMDAR function and memory retention and protected against the disruption of sensory gating produced by amphetamine.¹⁰

The central bioavailability of glycine in humans has not been adequately determined. Peripheral glycine administration produces clear dose-related elevations in both serum and CSF glycine levels.¹¹ The neural correlate of this increase in serum and CSF glycine availability remains unclear and requires further study. Although glycine and other glycine_B site agonists may not have clear detectable effects in cognition in young healthy human subjects, it may have acute cognitive effects in aging healthy subjects or in healthy subjects administered scopolamine or ketamine.¹²

Alterations in glycine metabolism and reductions in NMDAR function have been implicated in schizophrenia and several clinical trials report beneficial effects of adding glycine_B agonists on a chronic basis to ongoing antipsychotic treatments in schizophrenic patients.^{13–16} For the present study, we recruited healthy control subjects to avoid confounding effects of acute or chronic illness and current or past pharmacotherapy and examined whether the glycine condition has a cerebral metabolic profile different than the placebo-treated condition. Thus, it may be useful to establish in young healthy subjects whether glycine administration produces detectable effects on cerebral metabolism as a step toward further development of drugs that facilitate the function of glycine_B receptors as treatments for schizophrenia and other disorders associated with deficits in NMDAR function.

*Department of Psychiatry, Yale University School of Medicine, and †PET Center Yale School of Medicine, New Haven, CT; ‡Pfizer Inc., Groton, CT and §Oak Hill, VA.

Received January 30, 2006; accepted after revision July 27, 2006.

This study was supported by grant Y-007-04 from the Yale-Pfizer Bioimaging Alliance.

Address correspondence and reprint requests to Alexander Neumeister, MD, Molecular Imaging Program, Clinical Neuroscience Division, Yale University School of Medicine, MSC 151E, Room 9-174, Building 1, 950 Campbell Ave, West Haven, CT 06516. E-mail: alexander.neumeister@yale.edu.

Copyright © 2006 by Lippincott Williams & Wilkins

ISSN: 0271-0749/06/2606-0595

DOI: 10.1097/01.jcp.0000245558.14284.aa

The present study was designed to detect glycine effects on regional cerebral metabolic rate of glucose (rCMRGlucose) in healthy human subjects, and by doing so, evaluate whether positron emission tomography (PET) studies in healthy human subjects might serve as a platform for studying agents that might enhance NMDAR function.

METHODS

Subjects

Thirteen individuals were included into the protocol, and complete data from 12 individuals (4 women; age, 28.5 ± 10.5 years) were obtained and subjected to analysis. Subjects underwent psychiatric evaluation using the *Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Nonpatient Version*,¹⁷ and medical evaluation including physical examination, blood and urine analyses, and electrocardiogram. Healthy subjects, all nonsmokers, did not have a personal or family history of psychiatric disorders in first-degree relatives as determined by SCID and by a structured interview assessing family history.¹⁸ Women were studied during the follicular phase of the menstrual cycle. Urine tests including tests for urine cotinine on the day of each test day assured the drug-free and nonsmoking status of all subjects.

Challenge Study Design

A double-blind, randomized, balanced crossover study involving healthy control subjects was conducted. Healthy control subjects received on 2 separate days intravenous (1) glycine (200 mg/kg body weight for 45 minutes) and (2) saline. [¹⁸F]Fluorodeoxyglucose (FDG) was administered immediately after completion of the 45-minute infusion of glycine or placebo at the time when peak plasma and CSF concentrations of the study drug were expected. The test days were at least 1 week apart to avoid carryover effects from 1 test day to the other. Blood samples to measure plasma glycine and D-serine concentrations were taken at baseline and subsequent time points.

Brain Imaging and Imaging Data Analysis

Magnetic resonance imaging (MRI) scans (3 T) were collected in each subject before the PET scan procedures to (1) exclude individuals with anatomical abnormalities and (2) to coregister PET and MRI for image analysis.

PET data were collected using an ECAT EXACT HR⁺ PET scanner. Global CMRGlucose and rCMRGlucose (mg/100 g/min) were measured noninvasively by combining left ventricular chamber time-activity curve data with venous blood samples to give the input function needed to calculate the metabolic rate.¹⁹ The left ventricular input function was obtained from dynamic PET imaging of the heart with venous blood samples obtained concurrently during imaging after injection of a mean of 5.174 mCi [¹⁸F]FDG on day 1 and a mean of 5.170 mCi [¹⁸F]FDG on day 2. This was followed by a 20-minute emission and an 8-minute transmission brain scan at 45 minutes posttracer injection.

Cross-sectional images of the rCMRGlucose were computed from the plasma input and reconstructed tomographic data. Individual MPRAGE MR data were resliced to match the spatial orientation of PET image data and coregistered to individual glycine and placebo rCMRGlucose images. Regions of interest (ROIs) were defined manually with MEDx software (Sensor Systems; Sterling, VA). The whole-brain FDG uptake was measured using an MRI-based template. A priori-selected ROIs included the cerebellum, hippocampus, and the dorsolateral prefrontal cortex, regions that exhibit highest concentrations of GlyTs in association with high NMDAR expression.^{20–24} Changes in the glucose metabolism within individual ROIs were tested as well as relative regional changes in metabolism, normalized to global rCMRGlucose.

Statistical parametric mapping software (SPM2; Wellcome Department of Cognitive Neurology, London, UK) run on a Matlab 6.5 platform was used for voxel-based statistical analysis. Absolute glucose metabolism scans were spatially normalized to an FDG template, with voxel size 2 × 2 × 2 mm, in the Montreal Neurological Institute space. A mean of each subject's glycine and placebo absolute glucose utilization images was used as the source image for normalization. Images were smoothed using a Gaussian kernel of 12 mm full width half maximum. Comparison of glycine and placebo conditions was performed using a voxel-based paired *t* test. Results were reported on data with and without inclusion of global normalization and grand mean scaling. Brain versus nonbrain was determined with an explicit mask of all absolute glucose utilization images proportionally scaled to 0.8. Decreases in glucose metabolism were observed at a height threshold of *P* = 0.001 (uncorrected) and an extent threshold of 40 voxels. Significant clusters are reported by their size and maximum *Z* value (*Z*_{max}) and *x*, *y*, and *z* coordinates in Montreal Neurological Institute space.

Behavioral Assessments and Neuropsychological Testing

Behavioral measurements were collected on each study day at baseline, before administration of glycine/saline, and immediately after the PET study. Visual analogue scales were used to evaluate changes in drowsy and emotional feelings. Neuropsychological testing using the CogState computerized neuropsychological battery, which includes measures of attention/vigilance, visual, verbal and working memory, executive function, and speed of processing was done at baseline immediately before administration of glycine/saline. A postdosing assessment was performed immediately after the PET study.

Statistical Analysis

Drug and time effects on plasma levels were examined using a linear mixed model with a heterogeneous compound symmetry covariance structure and Bonferroni post hoc tests. Pearson correlations were used to evaluate the relationship between neuropsychological measures and plasma levels. Paired *t* tests were used to compare ROIs on the drug phases. Results were considered at *P* < 0.05, corrected.

RESULTS

Plasma Concentration Analysis Glycine

As expected, we found significant main effects of drug ($F_{1,11} = 331.75, P < 0.001$), time ($F_{10,23} = 59.91, P < 0.001$), and a significant drug by time interaction ($F_{1,11} = 61.47, P < 0.001$). Peak increases of plasma glycine concentration compared with baseline were found 45 minutes after initiation of the injection, at the time of the [^{18}F]FDG injection (Fig. 1).

Plasma Concentration Analysis D-Serine

Very similar results were found for plasma D-serine concentrations with significant main effects of drug ($F_{1,11} = 151.76, P < 0.001$), time ($F_{10,30} = 34.84, P < 0.001$), and a significant drug by time interaction ($F_{10,36} = 25.55, P < 0.001$). Peak increases of plasma D-serine concentration compared with baseline were found 45 minutes after initiation of the infusion, at the time of the [^{18}F]FDG infusion (Fig. 2).

Behavioral Effects

No statistically significant behavioral effects were found during administration of glycine or placebo (P values between 0.115 and 1.000).

Neuropsychological Testing

The analyses of variance indicated no significant interaction between assessment and treatment for any of the measures. Exploration of the interactions indicated that a significant difference was found between baseline and postdrug performance for verbal learning and memory, for both the placebo and glycine conditions. Furthermore, the effect sizes computed for these differences indicated large effects, where performance was poorer in the posttreatment




FIGURE 1. Plasma concentrations of glycine during administration of intravenous glycine versus placebo. The infusion was given over a period of 45 minutes between time 0 and 45. Injection of [^{18}F]FDG started at 45 minutes for 2 minutes. Data are presented as means \pm SEM.




FIGURE 2. Plasma concentrations of D-serine during administration of intravenous glycine versus placebo. The infusion was given during a period of 45 minutes between time 0 and 45. Injection of [^{18}F]FDG started at 45 minutes for 2 minutes. Data are presented as means \pm SEM.

(placebo or glycine) condition compared with baseline. Notably, these effects were not explained by concomitant fatigue or changes in motivation because only nonsignificant effects of drug administration were found on the behavioral assessments.

Region-of-interest Analysis

There was a significant reduction of whole-brain CMRglu during administration of glycine compared with placebo (5.83 ± 0.80 vs. 6.38 ± 0.89 ; $t = 2.60, df = 11, P = 0.023$; 9% decrease in CMRglu during administration of glycine vs. placebo). In the a priori-selected ROI, there was a significant reduction in the cerebellum (5.43 ± 0.74 vs. 6.07 ± 0.20 ; $t = -3.18, df = 11, P = 0.009$) and the dorsolateral prefrontal cortex (5.99 ± 0.96 vs. 6.56 ± 1.18 ; $t = -2.31, df = 11, P = 0.041$) and a nonsignificant reduction in the hippocampus (4.36 ± 0.85 vs. 4.88 ± 0.98 ; $t = -1.62, df = 11, P = 0.133$). When corrected for whole-brain CMRglu, rCMRglu differences were not significant (cerebellum, $t = -1.26, df = 11, P = 0.233$; dorsolateral prefrontal cortex, $t = 0.57, df = 11, P = 0.955$). There were no significant correlations between changes in glycine or D-serine levels and whole-brain CMRglu or rCMRglu in any of the selected ROI.

Statistical Parametric Mapping Analysis

Scans collected during administration of intravenous glycine showed a decrease in rCMRglu, relative to placebo condition (Table 1). A paired t test analyzing the absolute values resulted in suprathreshold clusters distributed throughout the brain ($P < 0.001, 40$ -voxel extent threshold). Decreases in absolute rCMRglu during administration of glycine versus placebo reached significance in the following regions: superior frontal gyrus ($KE_{\text{voxel extent}} = 215$; $P_{\text{corr}} < 0.006$; $z = 4.49$ at $-20, 52$, and -26); right cerebellum ($KE = 166$; $P_{\text{corr}} < 0.023$; $z = 4.39$ at $18, -76$, and -20); left

TABLE 1. Results of the Decrease in rCMRGlucose During Glycine Infusion (Relative to Placebo)

Cluster Level		Voxel Level							
P_{corr}	K_e	P_{unc}	P_{FWECor}	P_{FDRcor}	t	Z_e	P_{unc}	$x, y, \text{ and } z \text{ (mm)}$	Brain Region
0.006	215	0	0.382	0.043	7.93	4.49	0	-20, 52, and -16	Left superior frontal gyrus
0.023	166	0	0.484	0.043	7.55	4.39	0	18, -76, and -20	Right cerebellum
0.002	271	0	0.593	0.043	7.2	4.3	0	-16, -52, and -66	Left cerebellum
0.000	354	0	0.772	0.043	6.65	4.13	0	-34, -80, and -50	Left cerebellum
0.007	210	0	0.657	0.043	7.01	4.24	0	-64, -18, and 14	Left transverse temporal gyrus
0.294	77	0.02	0.252	0.043	8.55	4.64	0	32, -24, and -14	Right hippocampus
0.073	124	0	0.613	0.043	7.14	4.28	0	42, 8, and 2	Right insula
0.087	118	0.01	0.912	0.043	6.12	3.96	0	-34, -14, and 16	Left insula

Summary of regions with the most robust changes in rCMRGlucose during administration of glycine versus placebo. None of these regional changes were significant when corrected for whole-brain CMRGlucose.

Voxel size, 2.0, 2.0, and 2.0 mm (1 resel = 217.31 voxels); search volume, $S = 1,688,744 \text{ mm}^3 = 211,093 \text{ voxels} = 849.9 \text{ resels}$; smoothness full width half maximum, 10.6, 11.9, and 13.8 mm = 5.3, 5.9, and 6.9 voxels.

cerebellum ($K_e = 271$; $P_{\text{corr}} < 0.002$; $z = 4.30$ at -16, -52, and -66), left cerebellum ($K_e = 354$; $P_{\text{corr}} < 0.000$; $z = 4.12$ at -34, -80, and -50), and in the transverse temporal gyrus ($K_e = 210$; $P_{\text{corr}} < 0.007$; $z = 4.24$ at -64, -18, and 14). Areas on the threshold of significance included the right and left insula and the right hippocampus. No suprathreshold clusters were found for increased rCMRGlucose during intravenous glycine, without global normalization. The inclusion of global normalization in the analysis of absolute metabolic rate scans resulted in no suprathreshold clusters for both decreased and increased rCMRGlucose.

DISCUSSION

Intravenous administration of glycine resulted in a significant reduction of whole-brain CMRGlucose. Although we found regional effects of glycine on rCMRGlucose, these effects were no longer significant after correction for the global effects. A single administration of glycine does not induce behavioral changes in healthy control subjects. Also, there has been no benefit of glycine on the cognitive performance of the healthy adult individuals studied.

One important question raised by this study is whether the reduction in cortical metabolism was indicative of a facilitation of NMDAR function. Several earlier reports found that ketamine, a drug that blocks NMDAR function increased human cortical metabolism and blood flow in many brain areas.²⁵⁻²⁷ The mechanism underlying the stimulatory effects of the attenuation of NMDAR function are not clear, but may reflect attenuation of GABA neuronal activation²⁸ and a resulting disinhibition of glutamate and acetylcholine release.²⁹⁻³¹ Glycine, by facilitating NMDAR, would be expected to have the opposite effect of ketamine (ie, to reduce the tone of cortical excitatory neurotransmission). This step, in turn, would be expected to reduce cortical metabolism, as reflected in 18FDG-PET because of the stoichiometric relationship between glucose metabolism and

glutamatergic metabolism.³² Thus, the current data may suggest that administration of dose of glycine that was previously shown to increase CSF glycine levels approximately 4-fold¹¹ also produces a pattern of cerebral metabolic change consistent with facilitation of NMDA glutamate receptor function. However, plasma and CSF glycine levels may not indicate the synaptic level of glycine. The regional metabolic effects of glycine infusion in this study did not withstand appropriate statistical corrections. Thus, it is likely that these effects have a relatively small effect size, consistent with the absence of cognitive and behavioral effects of glycine in this study. It would be interesting to know whether there is a regional cerebral metabolic fingerprint for the ability of glycine pretreatment to attenuate cognitive and behavioral effects of the NMDAR antagonist, ketamine, in healthy human subjects.¹² It can be speculated that more specific effects of exogenous administration of glycine are found only in the presence of impaired NMDAR function, either experimentally induced by ketamine or in patient populations (ie, schizophrenic patients). Altered responses to glycine might be associated with heritable alterations in glycine or D-serine metabolism,³³ impaired NMDA receptor function, as may be the case in schizophrenia,³⁴ or increased NMDA receptor function, as may be the case in alcohol dependence.³⁵

The observation that glycine administration produces a cerebral metabolic signal that might be consistent with NMDAR facilitation in the absence of other behavioral effects may have implications for the development of 18FDG-PET as an approach for evaluating the effects of other approaches to facilitating NMDAR. In addition to glycine, D-cycloserine, D-alanine, D-serine, and a growing array of GlyT inhibitors are in varying stages of development as treatments for neuropsychiatric disorders. The current data raise the possibility that 18FDG-PET may detect brain effects of these agents even at doses and in populations where no behavioral signal is obtained. As a result, this approach may

help to validate the penetration of these agents into the brain in humans in the absence of more selective ligands to detect the degree of occupancy of their receptor targets.

ACKNOWLEDGMENTS

The authors thank Sue Kasserman, RN, for her recruitment efforts, and the Biostudies nursing staff, particularly Angelina M. Genovese, RN, MBA, and Elizabeth O'Donnell, RN, for their nursing support throughout the study.

REFERENCES

- Kemp JA, Leeson PD. The glycine site of the NMDA receptor—five years on. *Trends Pharmacol Sci.* 1993;14:20–25.
- Nong Y, Huang YQ, Ju Q, et al. Glycine binding primes NMDA receptor internalization. *Nature.* 2003;422:302–307.
- Danysz W, Parsons AC. Glycine and *N*-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. *Pharmacol Rev.* 1998;50:597–664.
- Roux M, Martinex-Maza R, Le Goff A, et al. The glial and the neuronal glycine transporters differ in their reactivity to sulfhydryl reagents. *J Biol Chem.* 2001;276:17699–17705.
- Chen L, Muhlhauser M, Yang CR. Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. *J Neurophysiol.* 2003;89:691–703.
- Bergeron R, Meyer TM, Coyle JT, et al. Modulation of *N*-methyl-D-aspartate receptor function by glycine transport. *Proc Natl Acad Sci USA.* 1998;95:15730–15734.
- Huang H, Barakat L, Wang D, et al. Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices. *J Physiol.* 2004;560:721–736.
- Kinney GG, Sur C, Burno M, et al. The glycine transporter type 1 inhibitor *N*-[3-(4-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. *J Neurosci.* 2003;23:7586–7591.
- Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. *Arch Gen Psychiatry.* 2005;62:1196–204.
- Tsai G, Ralph-Williams RJ, Martina M, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. *Proc Natl Acad Sci USA.* 2004;101:8485–8490.
- D'Souza DC, Gil R, Cassello K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. *Biol Psychiatry.* 2000;47:450–462.
- D'Souza DC, Gil R, Castello K, et al. Glycine-ketamine interactions in healthy humans. 36th Annual Meeting of the American College of Neuropsychopharmacology; December 8–12, 1997; Kona, HI.
- Javitt DC, Silip G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. *Int J Neuropsychopharmacol.* 2001;4:385–391.
- Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. *Schizophr Res.* 2004;66:89–96.
- Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. *Ann N Y Acad Sci.* 2003;1003:318–327.
- Tsai G, Yang L, Chung LC, et al. D-Serine added to antipsychotics for the treatment of schizophrenia. *Biol Psychiatry.* 1998;44:1081–1089.
- First MB, Gibbon M, Spitzer RL, et al. *Structured Clinical Interview for DSM-IV Axis I Disorders: Nonpatient Edition (SCID-I/NP)*. New York: Biometrics Department, New York State Psychiatric Institute; 1996.
- Maxwell ME. *Manual for the Family Interview for Genetic Studies (FIGS)*. Bethesda, MD: Clinical Neurogenetics Branch, National Institute of Mental Health; 1992.
- Moore DF, Altarescu G, Barker WC, et al. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. *Brain Res Bull.* 2003;62:231–240.
- Jursky F, Nelson N. Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain. *J Neurochem.* 1996;67:336–344.
- Goebel DJ. Quantitative gene expression of two types of glycine transporter in the rat central nervous system. *Brain Res Mol Brain Res.* 1996;40:139–142.
- Borowsky B, Mezey E, Hoffman BJ. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. *Neuron.* 1993;10:851–863.
- Adams RH, Sato K, Shimada S, et al. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. *J Neurosci.* 1995;15:2524–2532.
- Zafra F, Aragon C, Olivares L, et al. Glycine transporters are differentially expressed among CNS cells. *J Neurosci.* 1995;15:3952–3969.
- Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. *Neuropsychopharmacology.* 1995;13:9–19.
- Breier A, Malhotra AK, Pinals DA, et al. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. *Am J Psychiatry.* 1997;154:805–811.
- Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). *Eur Neuropsychopharmacol.* 1997;7:25–38.
- Grunze HC, Raimnie DG, Hasselmo ME, et al. NMDA-dependent modulation of CA1 local circuit inhibition. *J Neurosci.* 1996;16:2034–2043.
- Kim SH, Price MT, Olney JW, et al. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. *Mol Psychiatry.* 1999;4:344–352.
- Kikuchi T, Wang Y, Shinbori H, et al. Effects of ketamine and pentobarbitone on acetylcholine release from the rat frontal cortex in vivo. *Br J Anaesth.* 1997;79:128–130.
- Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J Neurosci.* 1997;17:2921–2927.
- Magistretti PJ, Pellerin L, Rothman DL, et al. Energy on demand. *Science.* 1999;283:496–497.
- Goldberg T, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. *Neuropsychopharmacology.* 2006;31:2022–2032.
- Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. *Mol Psychiatry.* 2006;11:118–119.
- Krystal JH, Petrakis I, Krasnicki S, et al. Altered responses to agonists of the strychnine-insensitive glycine NMDA coagonist (SIGLY) site in recently detoxified alcoholics. *Alcohol Clin Exp Res.* 1998;22:94A.